Clinical research progress of immunotherapy combined with chemoradiotherapy in the treatment of non-small cell lung cancer

Abstract

Lin Xianyong, Hu Xiang, Yin Haitao. Clinical research progress of immunotherapy combined with chemoradiotherapy in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(1): 56-60.

References33

[1]	Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98. DOI: 10.1056/NEJMoa011954. doi:10.1056/NEJMoa011954
[2]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi:10.1056/NEJMoa1606774
[3]	Britschgi C, Riesterer O, Burger IA, et al. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer[J]. Radiat Oncol, 2018, 13(1):102. DOI: 10.1186/s13014-018-1049-3. doi:10.1186/s13014-018-1049-3
[4]	白馨雅, 张金梦, 孙洋, 等. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8):500-504. DOI: 10.3760/cma.j.issn.1673-422X.2019.08.012. doi:10.3760/cma.j.issn.1673-422X.2019.08.012
[5]	Yamaguchi O, Kaira K, Hashimoto K, et al. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab[J]. Thorac Cancer, 2019, 10(4):992-1000. DOI: 10.1111/1759-7714.13044. doi:10.1111/1759-7714.13044pmid:30888716
[6]	Fiorica F, Belluomini L, Stefanelli A, et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination[J]. Am J Clin Oncol, 2018, 41(11):1101-1105. DOI: 10.1097/COC.0000000000000428. doi:10.1097/COC.0000000000000428
[7]	Bassanelli M, Ricciuti B, Giannarelli D, et al. Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study[J]. Tumori, 2021, 30089162-11004733. DOI: 10.1177/03008916211004733. doi:10.1177/03008916211004733
[8]	Tamiya A, Tamiya M, Nakahama K, et al. Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer[J]. Anticancer Res, 2017, 37(9):5199-5205. DOI: 10.21873/anticanres.11943. doi:10.21873/anticanres.11943
[9]	Furuta H, Yoshida T, Shimizu J, et al. Nivolumab enhances the inflammation of the irradiation field in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(11):1733-1736. DOI: 10.1016/j.jtho.2017.07.025. doi:10.1016/j.jtho.2017.07.025
[10]	Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer-the ETOP NICOLAS trial[J]. Lung Cancer, 2019, 133:83-87. DOI: 10.1016/j.lungcan.2019.05.001. doi:S0169-5002(19)30441-6pmid:31200833
[11]	Miyamoto S, Nomura R, Sato K, et al. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage Ⅳ non-small-cell lung cancer[J]. Jpn J Clin Oncol, 2019, 49(2):160-164. DOI: 10.1093/jjco/hyy171. doi:10.1093/jjco/hyy171pmid:30452687
[12]	Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895-903. DOI: 10.1016/S1470-2045(17)30380-7. doi:S1470-2045(17)30380-7pmid:28551359
[13]	Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial[J]. JAMA Oncol, 2020, 6(6):848-855. DOI: 10.1001/jamaoncol.2019.6731. doi:10.1001/jamaoncol.2019.6731pmid:32077891
[14]	Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer: Hoosier cancer research network LUN 14-179[J]. Cancer, 2020, 126(19):4353-4361. DOI: 10.1002/cncr.33083. doi:10.1002/cncr.33083
[15]	Anouti B, Althouse S, Durm G, et al. Prognostic variables associated with improved outcomes in patients with stage Ⅲ NSCLC treated with chemoradiation followed by consolidation pembrolizumab: a subset analysis of a phase Ⅱ study from the Hoosier Cancer Research Network LUN 14-179[J]. Clin Lung Cancer, 2020, 21(3):288-293. DOI: 10.1016/j.cllc.2019.06.009. doi:S1525-7304(19)30151-2pmid:32143966
[16]	Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282. DOI: 10.1001/jamaoncol.2019.1478. doi:10.1001/jamaoncol.2019.1478
[17]	Welsh J, Menon H, Chen DW, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001001. DOI: 10.1136/jitc-2020-001001. doi:10.1136/jitc-2020-001001
[18]	Yan X, Zhao YT, Liu Y, et al. Case report: low-dose decitabine plus anti-PD-1 inhibitor camrelizumab for previously treated advanced metastatic non-small cell lung cancer[J]. Front Oncol, 2020, 10:558572. DOI: 10.3389/fonc.2020.558572. doi:10.3389/fonc.2020.558572
[19]	Wei Z, Yang X, Ye X, et al. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer[J]. J Cancer Res Ther, 2019, 15(7):1629-1634. DOI: 10.4103/jcrt.JCRT_990_19. doi:10.4103/jcrt.JCRT_990_19
[20]	Li W, Wei Z, Yang X, et al. Salvage therapy of reactive capillary hemangiomas: apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer[J]. J Cancer Res Ther, 2019, 15(7):1624-1628. DOI: 10.4103/jcrt.JCRT_997_19. doi:10.4103/jcrt.JCRT_997_19
[21]	Socinski MA, Özgüroğlu M, Villegas A, et al. Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage Ⅲ non-small-cell lung cancer (PACIFIC)[J]. Clin Lung Cancer, 2021, 22(6):549-561. DOI: 10.1016/j.cllc.2021.05.009. doi:10.1016/j.cllc.2021.05.009
[22]	Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial[J]. Lancet Oncol, 2021, 22(6):824-835. DOI: 10.1016/S1470-2045(21)00149-2. doi:10.1016/S1470-2045(21)00149-2
[23]	Shaverdian N, Thor M, Shepherd AF, et al. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab[J]. Cancer Med, 2020, 9(13):4622-4631. DOI: 10.1002/cam4.3113. doi:10.1002/cam4.3113
[24]	Saito S, Abe T, Kobayashi N, et al. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer[J]. Clin Transl Radiat Oncol, 2020, 23:85-88. DOI: 10.1016/j.ctro.2020.05.006. doi:10.1016/j.ctro.2020.05.006
[25]	Inoue H, Ono A, Kawabata T, et al. Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer[J]. Invest New Drugs, 2020, 38(5):1612-1617. DOI: 10.1007/s10637-020-00917-2. doi:10.1007/s10637-020-00917-2
[26]	Lin SH, Lin Y, Yao LY, et al. Phase Ⅱ trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC[J]. J Thorac Oncol, 2020, 15(2):248-257. DOI: 10.1016/j.jtho.2019.10.024. doi:10.1016/j.jtho.2019.10.024
[27]	Qin A, Rengan R, Lee S, et al. A pilot study of atezolizumab plus hypofractionated image guided radiation therapy for the treatment of advanced non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):170-177. DOI: 10.1016/j.ijrobp.2019.10.047. doi:10.1016/j.ijrobp.2019.10.047
[28]	Nakashima K, Saruwatari K, Sato R, et al. Non-small-cell lung cancer with severe skin manifestations related to radiation recall dermatitis after atezolizumab treatment[J]. Intern Med, 2020, 59(9):1199-1202. DOI: 10.2169/internalmedicine.3937-19. doi:10.2169/internalmedicine.3937-19
[29]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104. DOI: 10.1056/NEJMoa1801946. doi:10.1056/NEJMoa1801946
[30]	Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019, 381(21):2020-2031. DOI: 10.1056/NEJMoa-1910231. doi:10.1056/NEJMoa-1910231
[31]	Boyer MJ, Gu L, Wang X, et al. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer[J]. Lung Cancer, 2016, 98:76-78. DOI: 10.1016/j.lungcan.2016.05.014. doi:10.1016/j.lungcan.2016.05.014
[32]	Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J]. Lancet Oncol, 2016, 17(3):299-308. DOI: 10.1016/S1470-2045(15)00544-6. doi:S1470-2045(15)00544-6pmid:26858122
[33]	Planchard D, Reinmuth N, Orlov S, et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer[J]. Ann Oncol, 2020, 31(5):609-618. DOI: 10.1016/j.annonc.2020.02.006. doi:S0923-7534(20)36041-5pmid:32201234

Clinical research progress of immunotherapy combined with chemoradiotherapy in the treatment of non-small cell lung cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References33

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[7]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[12]	Guo Ciliang, Jiang Chunping, Wu Junhua.Gut microbiome and tumor immunotherapy[J]. Journal of International Oncology, 2023, 50(7): 432-436.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[15]	Gu Anqin, Long Jinhua, Jin Feng.Clinical research progress of immunotherapy for nasopharyngeal carcinoma[J]. Journal of International Oncology, 2023, 50(5): 299-303.